Unlocked Nucleomonomer Agents (UNAs)
Arcturus’ unlocked nucleomonomer agents (UNAs) can improve the in vivo efficiency of small interfering RNA (siRNA)-mediated gene silencing and potentially improve the efficiency of messenger RNA (mRNA)-mediated protein replacement. UNAs are RNA analogues in which the C2′-C3′ bond of the ribose ring is absent (see figure below).
One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule. Addition of a single UNA in siRNA therapeutics can enable more efficient suppression of target protein production.
March 30, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
read more
March 1, 2021
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
read more
February 22, 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
read more
